论文部分内容阅读
费城染色体阳性的急性淋巴性白血病(Ph+ALL)是成人ALL的常见类型。众所周知,在酪氨酸酶抑制剂(TKI)出现之前,传统化疗包括强烈化疗治疗Ph+ALL效果差。异基因造血干细胞移植(allo-HSCT)能显著提高治愈率,成为Ph+ALL第一次完全缓解(CR1)后的标准一线治疗。近15年来,随着TKI在Ph+ALL中的广泛应用,TKI联合化疗明显改善了完全缓解(CR)率、CR深度和持续时间。Allo-HSCT是否仍为Ph+ALL患者CR1后的标准一线治疗出现了争议,尤其在儿童患
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is a common type of adult ALL. It is well known that traditional chemotherapy, including strong chemotherapeutic treatment of Ph + ALL, is ineffective prior to the appearance of tyrosinase inhibitor (TKI). Allo-HSCT can significantly improve the cure rate and become the standard first-line treatment after the first complete remission (CR1) of Ph + ALL. In the past 15 years, with the extensive use of TKI in Ph + ALL, TKI combined with chemotherapy significantly improved the complete remission (CR) rate, CR depth and duration. Whether Allo-HSCT remains the standard first-line treatment after CR1 in Ph + ALL patients is controversial, especially in children